Ovarian Cancer, Version 2.2020

被引：479

作者：

Armstrong, Deborah K. ^{[1
]}

Alvarez, Ronald D. ^{[2
]}

Bakkum-Gamez, Jamie N. ^{[3
]}

Barroilhet, Lisa ^{[4
]}

Behbakht, Kian ^{[5
]}

Berchuck, Andrew ^{[6
]}

Chen, Lee-may ^{[7
]}

Cristea, Mihaela ^{[8
]}

DeRosa, Maria

Eisenhauer, Eric L. ^{[9
]}

Gershenson, David M. ^{[10
]}

Gray, Heidi J. ^{[11
]}

Grisham, Rachel ^{[12
]}

Hakam, Ardeshir ^{[13
]}

Jain, Angela ^{[14
]}

Karam, Amer ^{[15
]}

Konecny, Gottfried E. ^{[16
]}

Leath, Charles A., III ^{[17
]}

Liu, Joyce ^{[18
]}

Mahdi, Haider ^{[19
,20
]}

Martin, Lainie ^{[21
]}

Matei, Daniela ^{[22
]}

McHale, Michael ^{[23
]}

McLean, Karen ^{[24
]}

Miller, David S. ^{[25
]}

O'Malley, David M. ^{[26
,27
]}

Percac-Lima, Sanja ^{[9
]}

Ratner, Elena ^{[28
]}

Remmenga, Steven W. ^{[29
]}

Vargas, Roberto ^{[19
,20
]}

Werner, Theresa L. ^{[30
]}

Zsiros, Emese ^{[31
]}

Burns, Jennifer L. ^{[32
]}

Engh, Anita M. ^{[32
]}

机构：

[1] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21287 USA

[2] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[3] Mayo Clin, Canc Ctr, Rochester, MN USA

[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[5] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[6] Duke Canc Inst, Durham, NC USA

[7] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[8] City Hope Natl Med Ctr, Los Angeles, CA USA

[9] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA

[12] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[14] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[15] Stanford Canc Inst, Stanford, CA USA

[16] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[17] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[18] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[19] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[20] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[21] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[22] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL USA

[23] UC San Diego Moores Canc Ctr, San Diego, CA USA

[24] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[25] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[26] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[27] Solove Res Inst, Columbus, OH USA

[28] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[29] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[30] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[31] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[32] Natl Comprehens Canc Network, Plymouth Meeting, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2021年 / 19卷 / 02期

关键词：

ADVANCED EPITHELIAL OVARIAN; FERTILITY-SPARING SURGERY; PHASE-III TRIAL; EARLY-STAGE OVARIAN; COOPERATIVE-ONCOLOGY-GROUP; TERM-FOLLOW-UP; PRIMARY CYTOREDUCTIVE SURGERY; CARBOPLATIN PLUS PACLITAXEL; INTRAVENOUS CISPLATIN PLUS; PRIMARY PERITONEAL CANCER;

D O I：

10.6004/jnccn.2021.0007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epithelial ovarian cancer is the leading cause of death from gyne-cologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypeshigh-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosar-coma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.

引用

页码：191 / +

页数：40

共 274 条

[1] Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer [J].

Abkevich, V. ;

Timms, K. M. ;

Hennessy, B. T. ;

Potter, J. ;

Carey, M. S. ;

Meyer, L. A. ;

Smith-McCune, K. ;

Broaddus, R. ;

Lu, K. H. ;

Chen, J. ;

Tran, T. V. ;

Williams, D. ;

Iliev, D. ;

Jammulapati, S. ;

FitzGerald, L. M. ;

Krivak, T. ;

DeLoia, J. A. ;

Gutin, A. ;

Mills, G. B. ;

Lanchbury, J. S. .

BRITISH JOURNAL OF CANCER, 2012, 107 (10) :1776-1782

[2] IMPROVED THERAPEUTIC INDEX OF CARBOPLATIN PLUS CYCLOPHOSPHAMIDE VERSUS CISPLATIN PLUS CYCLOPHOSPHAMIDE - FINAL REPORT BY THE SOUTHWEST-ONCOLOGY-GROUP OF A PHASE-III RANDOMIZED TRIAL IN STAGE-III AND STAGE-IV OVARIAN-CANCER [J].

ALBERTS, DS ;

GREEN, S ;

HANNIGAN, EV ;

OTOOLE, R ;

STOCKNOVACK, D ;

ANDERSON, P ;

SURWIT, EA ;

MALVLYA, VK ;

NAHHAS, WA ;

JOLLES, CJ .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (05) :706-717

[3] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[4] Aggressive surgical effort and improved survival in advanced-stage ovarian cancer [J].

Aletti, GD ;

Dowdy, SC ;

Gostout, BS ;

Jones, MB ;

Stanhope, CR ;

Wilson, TO ;

Podratz, KC ;

Cliby, WA .

OBSTETRICS AND GYNECOLOGY, 2006, 107 (01) :77-85

[5] Pattern of retroperitoneal dissemination of primary peritoneum cancer: Basis for rational use of lymphadenectomy [J].

Aletti, Giovanni D. ;

Powless, Cecelia ;

Bakkum-Gamez, Jamie ;

Wilson, Timothy O. ;

Podratz, Karl C. ;

Cliby, William A. .

GYNECOLOGIC ONCOLOGY, 2009, 114 (01) :32-36

[6] Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study [J].

Alletti, S. Gueli ;

Petrillo, M. ;

Vizzielli, G. ;

Bottoni, C. ;

Nardelli, F. ;

Costantini, B. ;

Quagliozzi, L. ;

Gallotta, V. ;

Scambia, G. ;

Fagotti, A. .

GYNECOLOGIC ONCOLOGY, 2016, 143 (03) :516-520

[7] Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study [J].

Alletti, Salvatore Gueli ;

Bottoni, Carolina ;

Fanfani, Francesco ;

Gallotta, Valerio ;

Chiantera, Vito ;

Costantini, Barbara ;

Cosentino, Francesco ;

Ercoli, Alfredo ;

Scambia, Giovanni ;

Fagotti, Anna .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (04) :503.e1-503.e6

[8] Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study [J].

Aravantinos, G ;

Fountzilas, G ;

Kosmidis, P ;

Dimopoulos, MA ;

Stathopoulos, GP ;

Pavlidis, N ;

Bafaloukos, D ;

Papadimitriou, C ;

Karpathios, S ;

Georgoulias, V ;

Papakostas, P ;

Kalofonos, HP ;

Grimani, E ;

Skarlos, DV .

ANNALS OF ONCOLOGY, 2005, 16 (07) :1116-1122

[9] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[10]

AstraZeneca, PRESCR INF OL TABL O

← 1 2 3 4 5 6 7 8 9 10 →